Yoon‐Koo Kang
Ulsan College(KR)Fujian Medical University(CN)Guangdong University of Technology(CN)Kyoto Prefectural University(JP)Xiamen University(CN)Yonsei University(KR)Royal North Shore Hospital(AU)Asan Medical Center(KR)University of Ulsan(KR)Robotics Research (United States)(US)Zhongshan Hospital of Xiamen University(CN)Kyoto University of Education(JP)Hyundai Motors (South Korea)(KR)
Publications by Year
Research Areas
Gastric Cancer Management and Outcomes, Gastrointestinal Tumor Research and Treatment, Colorectal Cancer Treatments and Studies, Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial(2010)7,196 cited
- → Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial(2008)5,801 cited
- → Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial(2017)4,261 cited
- → Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)2,247 cited
- → Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial(2019)1,630 cited